Waldman B, et al. - Authors intended to ascertain if fenofibrate produced sustained reductions in uric acid and gout attacks in participants aged 50–75 years with type 2 diabetes. Findings disclosed that uric acid concentrations lowered by 20% due to fenofibrate, and almost halved first on-study gout events over 5 years of treatment. The inference drawn was that fenofibrate could serve as a beneficial adjunct for preventing gout in diabetes.